1066P - Rapid and objective CT-scan prognostic scoring identifies patients with long-term clinical benefit on phase I trials

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Imaging, Diagnosis and Staging
Presenter Laurent Dercle
Citation Annals of Oncology (2016) 27 (6): 359-378. 10.1093/annonc/mdw378
Authors L. Dercle1, S. Ammari1, S. Champiat1, C. Massard2, C. Ferte3, M. Texier3, E. Lanoy2, L. Taihi3, R. Seban3, S. Aspeslagh4, S. Antoun4, L. Mahjoubi4, N. Kamsu-Kom4, C. Robert4, A. Marabelle4, M. Schlumberger5, J. Soria4, S. Postel-Vinay4
  • 1Nuclear Medicine, Institut de Cancérologie Gustave Roussy, 94800 - Villejuif/FR
  • 2Drug Development Department, Institut Gustave Roussy, Villejuif/FR
  • 3Département De Médecine Oncologique, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 4Drug Development Department (ditep), Institut Gustave Roussy, 94800 - Villejuif/FR
  • 5Nuclear Endocrinology, Institut Gustave Roussy, Villejuif/FR

Abstract

Background

Drugs targeting programmed death receptor-1 and its ligand PD-L1 (aPD(L)1) have shown activity in multiple malignancies. Considering their novel mechanism of action, whether traditional prognostic scores also apply to patients receiving aPD(L)1 is unknown. We investigated whether a baseline 3-points (pts) CT-scan (PS3-CT) score and a 7-pts prognostic score (PS7) allowed identifying long-term survivors on aPD(L)1 as compared to molecularly targeted agents (MTA).

Methods

We reviewed all consecutive patients enrolled in phase I (PhI) trials evaluating aPD(L)1 between 12/2011 and 07/2015, and in PhI trials evaluating MTA between 03/2008 and 07/2012. PS3-CT was calculated using high tumor burden (TB > 9 cm), low-skeletal muscle index (SMI< 53 cm2.m-2) and non-pulmonary visceral metastases (NPVM) (1 pt each). PS7 was calculated by adding performance status >1, low albumin, high LDH and >2 metastases (1 pt. each). Effect on overall survival (OS) of each parameter was tested using Kaplan Meier and Multivariate Cox analyses.

Results

461 patients (251 receiving aPD(L)1 and 210 receiving MTA) were included. Patients characteristics were comparable in both groups, excepted for melanoma patients (40% and 5% of the patients in the aPD(L)1 and MTA groups, respectively). PS3-CT was a significant independent predictor of OS in the aPD(L)1 (HR = 1.39 [95%CI = 1.07-1.81]; p = 0.01) and MTA (HR = 1.35 [95%CI = 1.08-1.68]; p = 0.01) groups, when compared to the Royal Marsden Hospital, Barbot and AJCC scores. High-TB and low-SMI were independent predictors of OS (HR = 2.00 [95%CI = 1.38-2.88], p 

Conclusions

Objective and rapid risk scoring based on three CT-scan parameters allows identifying patients with prolonged OS on anti-PD(L)1 and MTA PhI trials, independently from conventional clinico-biological prognostic scores.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

None

Disclosure

All authors have declared no conflicts of interest.